drugset / Trial / NCT02678234

An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu

NCT02678234

Phase 3 Withdrawn GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the short term efficacy of the Theraflu Aktiv powder for oral solution in the Russian population as compared to an untreated group to support the indication of "Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion".

Timeline

Start
2017-02-01
Primary completion
2017-04-01
Completion
2017-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 500 mg Oral
Subject Phenylephrine Small molecule 10 mg Oral
Subject Vitamin C Other / unclassified 200 mg Oral